Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 5th edition, 486 pages

Free download


  Lung Cancer

  Free Subscription


Articles published in Eur Respir J

Retrieve available abstracts of 68 articles:
HTML format



Single Articles


    November 2020
  1. INFANTE MV, Cardillo G
    Lung cancer screening in never-smokers: facts and remaining issues.
    Eur Respir J. 2020;56.
    PubMed    


  2. VALLIERES E
    The optimal treatment of stage I nonsmall cell lung cancer in the era of SABR and modern day lung resections.
    Eur Respir J. 2020;56.
    PubMed    


    October 2020
  3. GAGA M, Chorostowska-Wynimko J, Horvath I, Tammemagi MC, et al
    Validation of Lung EpiCheck(R), a novel methylation-based blood assay, for the detection of lung cancer in European and Chinese high-risk individuals.
    Eur Respir J. 2020 Oct 29. pii: 13993003.02682-2020.
    PubMed     Abstract available


  4. BOUSEMA JE, Aarts MJ, Dijkgraaf MGW, Annema JT, et al
    Trends in mediastinal nodal staging and its impact on unforeseen N2 and survival in lung cancer.
    Eur Respir J. 2020 Oct 2. pii: 13993003.01549-2020.
    PubMed     Abstract available


    August 2020
  5. LEGENDRE M, Butt A, Borie R, Debray MP, et al
    Functional assessment and phenotypic heterogeneity of SFTPA1 and SFTPA2 mutations in interstitial lung diseases and lung cancer.
    Eur Respir J. 2020 Aug 27. pii: 13993003.02806-2020.
    PubMed     Abstract available


  6. GARNER JL, Shah PL
    Challenges of evaluating lung function as part of cancer care during the COVID-19 pandemic.
    Eur Respir J. 2020;56.
    PubMed    


    July 2020
  7. SULLIVAN FM, Mair FS, Anderson W, Armory P, et al
    Earlier diagnosis of lung cancer in a randomised trial of an autoantibody blood test followed by imaging.
    Eur Respir J. 2020 Jul 30. pii: 13993003.00670-2020.
    PubMed     Abstract available


  8. FRANKS KN, McParland L, Webster J, Baldwin DR, et al
    SABRTOOTH: A randomised controlled feasibility study of Stereotactic Ablative Radiotherapy (SABR) with surgery in paTients with peripheral stage I nOn-small cell lung cancer (NSCLC) cOnsidered To be at Higher risk of complications from surgical resect
    Eur Respir J. 2020 Jul 2. pii: 13993003.00118-2020.
    PubMed     Abstract available


    June 2020
  9. KIM YW, Kang HR, Kwon BS, Lim SY, et al
    Low-dose chest computed tomographic screening and invasive diagnosis of pulmonary nodules for lung cancer in never-smokers.
    Eur Respir J. 2020 Jun 1. pii: 13993003.00177-2020.
    PubMed     Abstract available


    May 2020
  10. LAVOLE A, Greillier L, Mazieres J, Monnet I, et al
    First-Line Carboplatin Plus Pemetrexed with Pemetrexed Maintenance in HIV+ Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: The Phase II IFCT-1001 CHIVA Trial.
    Eur Respir J. 2020 May 22. pii: 13993003.02066-2019.
    PubMed     Abstract available


  11. RASKIN J, Lebeer M, De Bondt C, Wener R, et al
    Cancer in the time of COVID-19: expert opinion on how to adapt current practice.
    Eur Respir J. 2020;55.
    PubMed    


    March 2020
  12. SUISSA S, Ernst P
    Avoiding immortal time bias in observational studies.
    Eur Respir J. 2020;55.
    PubMed    


  13. RAYMAKERS AJN, Sadatsafavi M, Sin DD, FitzGerald JM, et al
    Avoiding immortal time bias in observational studies.
    Eur Respir J. 2020;55.
    PubMed    


    February 2020
  14. BERGHMANS T, Dingemans AM, Hendriks LEL, Cadranel J, et al
    Immunotherapy for nonsmall cell lung cancer: a new therapeutic algorithm.
    Eur Respir J. 2020;55.
    PubMed    


  15. KAUCZOR HU, Baird AM, Blum TG, Bonomo L, et al
    ESR/ERS statement paper on lung cancer screening.
    Eur Respir J. 2020;55.
    PubMed     Abstract available


    January 2020
  16. HENDRIKS LEL, Cadranel J, Berghmans T
    Current challenges in the management of nonsmall cell lung cancer brain metastases.
    Eur Respir J. 2020;55.
    PubMed    


    November 2019
  17. SUISSA S, Dell'Aniello S, Gonzalez AV, Ernst P, et al
    Inhaled corticosteroid use and the incidence of lung cancer in COPD.
    Eur Respir J. 2019 Nov 19. pii: 13993003.01720-2019.
    PubMed     Abstract available


    September 2019
  18. SPIRO SG, Shah PL, Rintoul RC, George J, et al
    Sequential screening for lung cancer in a high-risk group: randomised controlled trial.
    Eur Respir J. 2019 Sep 19. pii: 13993003.00581-2019.
    PubMed     Abstract available



  19. "Screening for lung cancer: time for large-scale screening by chest computed tomography." Dekel Shlomi, Ronny Ben-Avi, Gingy Ronen Balmor, Amir Onn and Nir Peled. Eur Respir J 2014; 44: 217-238.
    Eur Respir J. 2019;54.
    PubMed    


  20. SOLTANI A, Mahmood MQ, Reid DW, Walters EH, et al
    Cancer-protective effects of inhaled corticosteroids in COPD are likely related to modification of epithelial activation.
    Eur Respir J. 2019;54.
    PubMed    


    August 2019
  21. OBERT M
    Are estimations of radiomic image markers dispensable due to recent deep learning findings?
    Eur Respir J. 2019;54.
    PubMed    


    July 2019
  22. DENG HY, Zhou Q
    Lobectomy should remain the first choice for treating early stage nonsmall cell lung cancer.
    Eur Respir J. 2019;54.
    PubMed    


  23. LU W, Sharma P, Eapen MS, Sohal SS, et al
    Inhaled corticosteroids attenuate epithelial mesenchymal transition: implications for COPD and lung cancer prophylaxis.
    Eur Respir J. 2019;54.
    PubMed    


    June 2019
  24. SEIJO LM, Soriano JB, Peces-Barba G
    New evidence on the chemoprevention of inhaled steroids and the risk of lung cancer in COPD.
    Eur Respir J. 2019;53.
    PubMed    


  25. BERZENJI L, Van Schil PE
    Surgery or stereotactic body radiotherapy for early-stage lung cancer: two sides of the same coin?
    Eur Respir J. 2019;53.
    PubMed    


  26. KRISTOF AS, Ortega VE
    The discovery of novel mechanisms for lymphangioleiomyomatosis pathogenesis through GWAS: a rarity in rare respiratory disorders.
    Eur Respir J. 2019;53.
    PubMed    


  27. AMAT B, Sapia S
    A journey to the centre of the mediastinal lymph nodes.
    Eur Respir J. 2019;53.
    PubMed    


    May 2019
  28. GRACIE K, Kennedy MPT, Esterbrook G, Smith G, et al
    The proportion of lung cancer patients attending UK lung cancer clinics who would have been eligible for low-dose CT screening.
    Eur Respir J. 2019 May 16. pii: 13993003.02221-2018.
    PubMed    


    April 2019
  29. WIJMANS L, Yared J, de Bruin DM, Meijer SL, et al
    Needle-based confocal laser endomicroscopy (nCLE) for real-time diagnosing and staging of lung cancer.
    Eur Respir J. 2019 Apr 25. pii: 13993003.01520-2018.
    PubMed     Abstract available


  30. RAYMAKERS AJN, Sadatsafavi M, Sin DD, FitzGerald JM, et al
    Inhaled corticosteroids and the risk of lung cancer in chronic obstructive pulmonary disease (COPD): a population-based cohort study.
    Eur Respir J. 2019 Apr 7. pii: 13993003.01257-2018.
    PubMed     Abstract available


    March 2019
  31. DETILLON DEMA, Aarts MJ, De Jaeger K, Van Eijck CHJ, et al
    Video-assisted thoracic lobectomy versus stereotactic body radiotherapy for stage I non-small cell lung cancer in elderly patients: a propensity matched comparative analysis.
    Eur Respir J. 2019 Mar 28. pii: 13993003.01561-2018.
    PubMed     Abstract available


    February 2019
  32. CASAL RF, Sepesi B, Sagar AS, Tschirren J, et al
    Centrally-located lung cancer and risk of occult nodal disease: an objective evaluation of multiple definitions of tumor centrality with a dedicated imaging software.
    Eur Respir J. 2019 Feb 28. pii: 13993003.02220-2018.
    PubMed     Abstract available


    January 2019
  33. SPENCER KL, Kennedy MPT, Lummis KL, Ellames DAB, et al
    Surgery or radiotherapy for stage I lung cancer? An intention to treat analysis.
    Eur Respir J. 2019 Jan 11. pii: 13993003.01568-2018.
    PubMed     Abstract available


  34. SHIN SH, Jeong DY, Lee KS, Cho JH, et al
    Which definition of central tumour is more predictive of occult mediastinal metastasis in non-small cell lung cancer patients with radiologic N0 disease?
    Eur Respir J. 2019 Jan 11. pii: 13993003.01508-2018.
    PubMed     Abstract available


    December 2018
  35. LU J, Zhong H, Chu T, Zhang X, et al
    Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for non-small cell lung cancer therapy.
    Eur Respir J. 2018 Dec 21. pii: 13993003.01562-2018.
    PubMed     Abstract available


  36. CROMBAG LMM, Dooms C, Stigt JA, Tournoy KG, et al
    Systematic and combined endosonographic staging of lung cancer (SCORE Study).
    Eur Respir J. 2018 Dec 21. pii: 13993003.00800-2018.
    PubMed     Abstract available


    October 2018
  37. RICH AL, Baldwin DR, Beckett P, Berghmans T, et al
    ERS Statement on harmonised standards for lung cancer registration and lung cancer services in Europe.
    Eur Respir J. 2018 Oct 25. pii: 13993003.00610-2018.
    PubMed     Abstract available


    September 2018
  38. MEYER G, Besse B, Doubre H, Charles-Nelson A, et al
    Antitumor Effect of Low Molecular Weight Heparin in Localised Lung Cancer A Phase III Clinical Trial.
    Eur Respir J. 2018 Sep 27. pii: 13993003.01220-2018.
    PubMed     Abstract available


    August 2018
  39. VISSER S, Huisbrink J, van 't Veer NE, van Toor JJ, et al
    Renal impairment during pemetrexed maintenance in patients with advanced non-small-cell lung cancer: a cohort study.
    Eur Respir J. 2018 Aug 23. pii: 13993003.00884-2018.
    PubMed     Abstract available


  40. VOLLMER I, Sanchez M, Rami-Porta R
    Lung cancer staging: imagine fewer images.
    Eur Respir J. 2018;52.
    PubMed    


  41. TOURNOY KG, Van Meerbeeck JP
    Lung cancer staging: imagine fewer images.
    Eur Respir J. 2018;52.
    PubMed    


    June 2018
  42. LOUBIERE S, Barlesi F, Missy P, Morin F, et al
    Cost-effectiveness of biomarker testing for treatment choices in advanced non-small cell lung carcinoma: impact of diagnostic strategies and their turnaround times.
    Eur Respir J. 2018;51.
    PubMed    


  43. UGUEN A
    Cost-effectiveness of biomarker testing for treatment choices in advanced non-small cell lung carcinoma: impact of diagnostic strategies and their turnaround times.
    Eur Respir J. 2018;51.
    PubMed    


  44. MASSARD G, Tabin N, Mitchell S, Batirel H, et al
    A harmonised European training syllabus for thoracic surgery: report from the ESTS/ERS task force group.
    Eur Respir J. 2018;51.
    PubMed    


  45. KURMI OP
    Is low level of vitamin D a marker of poor health, or a cause?
    Eur Respir J. 2018;51.
    PubMed    


    May 2018
  46. MIKESCH JH, Schwammbach D, Hartmann W, Schmidt LH, et al
    Reptin drives tumour progression and resistance to chemotherapy in non-small cell lung cancer.
    Eur Respir J. 2018 May 31. pii: 13993003.01637-2017.
    PubMed     Abstract available


  47. SANDRI BJ, Kaplan A, Hodgson SW, Peterson M, et al
    Multi-Omic Molecular Profiling of Lung Cancer in Chronic Obstructive Pulmonary Disease.
    Eur Respir J. 2018 May 24. pii: 13993003.02665-2017.
    PubMed     Abstract available


  48. SUN YQ, Brumpton BM, Bonilla C, Lewis SJ, et al
    Serum 25-hydroxyvitamin D levels and risk of lung cancer and histologic types: a Mendelian randomisation analysis of the HUNT study.
    Eur Respir J. 2018 May 10. pii: 13993003.00329-2018.
    PubMed     Abstract available


  49. SCHEERENS C, Beernaert K, Pype P, Cohen J, et al
    Comparing the use and timing of palliative care services in COPD and lung cancer: a population-based survey.
    Eur Respir J. 2018;51.
    PubMed    


  50. VAN MEERBEECK JP, Jansen G, Giovannetti E, Peters GJ, et al
    Aminopeptidase antibodies in mesothelioma: new wine deserves new sacks.
    Eur Respir J. 2018;51.
    PubMed    


    April 2018
  51. RAMI-PORTA R, Call S, Dooms C, Obiols C, et al
    Lung cancer staging: a concise update.
    Eur Respir J. 2018 Apr 26. pii: 13993003.00190-2018.
    PubMed     Abstract available


  52. DECALUWE H, Dooms C, De Leyn P, Thomas P, et al
    Adding an invasive procedure will not necessarily change treatment or outcome of NSCLC patients with preoperative clinical N1 disease.
    Eur Respir J. 2018;51.
    PubMed    


  53. ADDEO A, Banna G
    Adding an invasive procedure will not necessarily change treatment or outcome of NSCLC patients with preoperative clinical N1 disease.
    Eur Respir J. 2018;51.
    PubMed    


    March 2018
  54. ZUGAZAGOITIA J, Biosca M, Olivera J, Eugenia Olmedo M, et al
    Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small-cell lung cancer.
    Eur Respir J. 2018 Mar 21. pii: 13993003.02431-2017.
    PubMed    


  55. LOUBIERE S, Drezet A, Beau-Faller M, Moro-Sibilot D, et al
    Cost-effectiveness of KRAS, EGFR and ALK testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study.
    Eur Respir J. 2018;51.
    PubMed     Abstract available


  56. UGUEN M, Dewitte JD, Lodde B, Marcorelles P, et al
    Asbestos-related lung cancers are rarely associated with ALK, ROS1 and RET rearrangements.
    Eur Respir J. 2018;51.
    PubMed    


    December 2017
  57. DECALUWE H, Dooms C, D'Journo XB, Call S, et al
    Mediastinal staging by videomediastinoscopy in clinical N1 non-small cell lung cancer: a prospective multicentre study.
    Eur Respir J. 2017;50.
    PubMed     Abstract available


    October 2017
  58. SUN YQ, Chen Y, Langhammer A, Skorpen F, et al
    Passive smoking in relation to lung cancer incidence and histologic types in Norwegian adults: the HUNT study.
    Eur Respir J. 2017;50.
    PubMed    


  59. PARIS C, Do P, Mastroianni B, Dixmier A, et al
    Association between lung cancer somatic mutations and occupational exposure in never-smokers.
    Eur Respir J. 2017;50.
    PubMed     Abstract available


    August 2017
  60. TOMASINI P, Brosseau S, Mazieres J, Merlio JP, et al
    EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice.
    Eur Respir J. 2017;50.
    PubMed     Abstract available


  61. GLATZER M, Rittmeyer A, Muller J, Opitz I, et al
    Treatment of limited disease small cell lung cancer: the multidisciplinary team.
    Eur Respir J. 2017;50.
    PubMed     Abstract available


    July 2017
  62. PLUVY J, Brosseau S, Naltet C, Opsomer MA, et al
    Lazarus syndrome in nonsmall cell lung cancer patients with poor performance status and major leukocytosis following nivolumab treatment.
    Eur Respir J. 2017;50.
    PubMed    


    May 2017
  63. AAMLI GAGNAT A, Gjerdevik M, Gallefoss F, Coxson HO, et al
    Incidence of non-pulmonary cancer and lung cancer by amount of emphysema and airway wall thickness: a community-based cohort.
    Eur Respir J. 2017;49.
    PubMed     Abstract available


    April 2017
  64. TIAN Q, Deng WJ, Li ZW
    Identification of a novel crizotinib-sensitive BCL11A-ALK gene fusion in a nonsmall cell lung cancer patient.
    Eur Respir J. 2017;49.
    PubMed    


  65. KHIROYA H, Moore JS, Ahmad N, Kay J, et al
    IRP2 as a potential modulator of cell proliferation, apoptosis and prognosis in nonsmall cell lung cancer.
    Eur Respir J. 2017;49.
    PubMed     Abstract available


  66. CALVAYRAC O, Pradines A, Pons E, Mazieres J, et al
    Molecular biomarkers for lung adenocarcinoma.
    Eur Respir J. 2017;49.
    PubMed     Abstract available


    March 2017
  67. LEDUC C, Antoni D, Charloux A, Falcoz PE, et al
    Comorbidities in the management of patients with lung cancer.
    Eur Respir J. 2017;49.
    PubMed     Abstract available


  68. DE PERROT M, Dong Z, Bradbury P, Patsios D, et al
    Impact of tumour thickness on survival after radical radiation and surgery in malignant pleural mesothelioma.
    Eur Respir J. 2017;49.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: